Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Int J Pharm. 2024 Mar 25;653:123879. doi: 10.1016/j.ijpharm.2024.123879. Epub 2024 Feb 4.
Phospholipid-based nanosystems show promising potentials for oral administration of hydrophobic drugs. The study introduced a novel approach to optimize posaconazole-loaded phospholipid-based nanoformulation using the design of experiments, machine learning, and Technique for Order of Preference by Similarity to the Ideal Solution. These approaches were used to investigate the impact of various variables on the encapsulation efficiency (EE), particle size, and polydispersity index (PDI). The optimized formulation, with %EE of ∼ 74 %, demonstrated a particle size and PDI of 107.7 nm and 0.174, respectively. The oral pharmacokinetic profiles of the posaconazole suspension, empty nanoformulation + drug suspension, and drug-loaded nanoformulation were evaluated. The nanoformulation significantly increased maximum plasma concentration and the area under the drug plasma concentration-time curve (∼3.9- and 6.2-fold, respectively) and could be administered without regard to meals. MTT and histopathological examinations were carried out to evaluate the safety of the nanoformulation and results exhibited no significant toxicity. Lymphatic transport was found to be the main mechanism of oral delivery. Caco-2 cell studies demonstrated that the mechanism of delivery was not based on an increase in cellular uptake. Our study represents a promising strategy for the development of phospholipid-based nanoformulations as efficient and safe oral delivery systems.
基于磷脂的纳米系统在经口给予疏水性药物方面显示出有前景的潜力。本研究采用实验设计、机器学习和理想溶液相似性偏好排序技术,介绍了一种优化泊沙康唑负载磷脂纳米制剂的新方法。这些方法用于研究各种变量对包封效率(EE)、粒径和多分散指数(PDI)的影响。优化后的制剂的 EE 约为 74%,粒径和 PDI 分别为 107.7nm 和 0.174。评价了泊沙康唑混悬液、空纳米制剂+药物混悬液和载药纳米制剂的口服药代动力学特征。纳米制剂显著增加了最大血浆浓度和药物血浆浓度-时间曲线下面积(分别约为 3.9 倍和 6.2 倍),并且可以不考虑进餐进行给药。进行了 MTT 和组织病理学检查以评估纳米制剂的安全性,结果显示无显著毒性。发现淋巴转运是口服给药的主要机制。Caco-2 细胞研究表明,该传递机制不是基于细胞摄取的增加。本研究代表了开发基于磷脂的纳米制剂作为高效和安全的口服递药系统的一种有前景的策略。